Review




Structured Review

Conkwest Inc human natural killer (nk)-92 176v cells
Human Natural Killer (Nk) 92 176v Cells, supplied by Conkwest Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human natural killer (nk)-92 176v cells/product/Conkwest Inc
Average 90 stars, based on 1 article reviews
human natural killer (nk)-92 176v cells - by Bioz Stars, 2026-03
90/100 stars

Images



Similar Products

90
Conkwest Inc human natural killer (nk)-92 176v cells
Human Natural Killer (Nk) 92 176v Cells, supplied by Conkwest Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human natural killer (nk)-92 176v cells/product/Conkwest Inc
Average 90 stars, based on 1 article reviews
human natural killer (nk)-92 176v cells - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Conkwest Inc human nk-92 176v cells
(A) Treatment schedule following Day 0 tumor challenge with minimum lethal dose of tumors. Antibody treatments were given by IV tail vein injections: 200 μg treatment antibody, 10 × 106 effector human <t>NK-92-176V</t> cells, and 5 × 104 IU IL-2. Bioluminescence imaging monitored mice challenged with luciferase-expressing tumors: (B) JeKo-1 (MCL) or (C) RS4;11 (ALL). Experimental groups received treatment of chimeric BAFF-R mAbs (C55 or C90, as indicated). Control group mice received PBS, NK cells alone, or rituximab on the same schedule. Data are representative of three independent experiments.
Human Nk 92 176v Cells, supplied by Conkwest Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human nk-92 176v cells/product/Conkwest Inc
Average 90 stars, based on 1 article reviews
human nk-92 176v cells - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


(A) Treatment schedule following Day 0 tumor challenge with minimum lethal dose of tumors. Antibody treatments were given by IV tail vein injections: 200 μg treatment antibody, 10 × 106 effector human NK-92-176V cells, and 5 × 104 IU IL-2. Bioluminescence imaging monitored mice challenged with luciferase-expressing tumors: (B) JeKo-1 (MCL) or (C) RS4;11 (ALL). Experimental groups received treatment of chimeric BAFF-R mAbs (C55 or C90, as indicated). Control group mice received PBS, NK cells alone, or rituximab on the same schedule. Data are representative of three independent experiments.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Article Title: Novel BAFF-receptor antibody to natively folded recombinant protein eliminates drug resistant human B-cell malignancies in vivo

doi: 10.1158/1078-0432.CCR-17-1193

Figure Lengend Snippet: (A) Treatment schedule following Day 0 tumor challenge with minimum lethal dose of tumors. Antibody treatments were given by IV tail vein injections: 200 μg treatment antibody, 10 × 106 effector human NK-92-176V cells, and 5 × 104 IU IL-2. Bioluminescence imaging monitored mice challenged with luciferase-expressing tumors: (B) JeKo-1 (MCL) or (C) RS4;11 (ALL). Experimental groups received treatment of chimeric BAFF-R mAbs (C55 or C90, as indicated). Control group mice received PBS, NK cells alone, or rituximab on the same schedule. Data are representative of three independent experiments.

Article Snippet: Human NK-92 176V cells were obtained from Conkwest Inc. (San Diego, CA).

Techniques: Imaging, Luciferase, Expressing